ForsetiMed: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
ForsetiMed
Largest movements
- Current investments +€100,000
up €100,000 (+200.0%), from €50,000 to €150,000
- Cash -€19,181
down €19,181 (-7.0%), from €272,394 to €253,213
mainly Current investments (-€100,000) and Tax, wage and social debts (-€3,189)
- Reserves +€85,299
up €85,299 (+27.9%), from €306,180 to €391,479
- Gross operating margin -€52,230
down €52,230 (-30.4%), from €172,046 to €119,815
- Taxes -€13,977
down €13,977 (-28.1%), from €49,717 to €35,740
- Financial income +€2,390
up €2,390 (+423.8%), from €564 to €2,954
- Financial charges -€1,973
down €1,973 (-62.4%), from €3,162 to €1,189
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €354,706 | €435,240 | +€80,534 | +22.7% |
| Fixed assets | 21/28 | €280 | €139 | -€142 | -50.5% |
| Tangible fixed assets | 22/27 | €280 | €139 | -€142 | -50.5% |
| Furniture and vehicles | 24 | €280 | €139 | -€142 | -50.5% |
| Current assets | 29/58 | €354,426 | €435,102 | +€80,676 | +22.8% |
| Amounts receivable within one year | 40/41 | €29,369 | €29,212 | -€157 | -0.5% |
| Trade receivables | 40 | €29,369 | €26,215 | -€3,154 | -10.7% |
| Other amounts receivable | 41 | - | €2,997 | +€2,997 | |
| Current investments | 50/53 | €50,000 | €150,000 | +€100,000 | +200.0% |
| Cash at bank and in hand | 54/58 | €272,394 | €253,213 | -€19,181 | -7.0% |
| Deferred charges and accrued income | 490/1 | €2,663 | €2,677 | +€14 | +0.5% |
| Total equity and liabilities | 10/49 | €354,706 | €435,240 | +€80,534 | +22.7% |
| Equity | 10/15 | €322,180 | €407,479 | +€85,299 | +26.5% |
| Contributions | 10/11 | €16,000 | €16,000 | = | 0.0% |
| Reserves | 13 | €306,180 | €391,479 | +€85,299 | +27.9% |
| Distributable reserves | 133 | €306,180 | €391,479 | +€85,299 | +27.9% |
| Amounts payable | 17/49 | €32,526 | €27,762 | -€4,764 | -14.6% |
| Amounts payable within one year | 42/48 | €32,526 | €27,762 | -€4,764 | -14.6% |
| Trade debts | 44 | €748 | €1,123 | +€375 | +50.1% |
| Suppliers | 440/4 | €748 | €1,123 | +€375 | +50.1% |
| Taxes, remuneration and social security | 45 | €29,828 | €26,639 | -€3,189 | -10.7% |
| Taxes | 450/3 | €29,828 | €26,639 | -€3,189 | -10.7% |
| Other amounts payable | 47/48 | €1,951 | - | -€1,951 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,396 | €142 | -€1,254 | -89.8% |
| Other operating charges | 640/8 | €387 | €400 | +€12 | +3.2% |
| Gross operating margin | 9900 | €172,046 | €119,815 | -€52,230 | -30.4% |
| Operating profit (loss) | 9901 | €170,262 | €119,274 | -€50,988 | -29.9% |
| Financial income | 75/76B | €564 | €2,954 | +€2,390 | +423.8% |
| Recurring financial income | 75 | €564 | €2,954 | +€2,390 | +423.8% |
| Financial charges | 65/66B | €3,162 | €1,189 | -€1,973 | -62.4% |
| Recurring financial charges | 65 | €3,162 | €1,189 | -€1,973 | -62.4% |
| Profit (loss) for the period before taxes | 9903 | €167,664 | €121,039 | -€46,625 | -27.8% |
| Income taxes | 67/77 | €49,717 | €35,740 | -€13,977 | -28.1% |
| Profit (loss) for the period | 9904 | €117,947 | €85,299 | -€32,648 | -27.7% |
| Profit (loss) for the period to be appropriated | 9905 | €117,947 | €85,299 | -€32,648 | -27.7% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 6 October 2026 via checked.be.